GEN News Highlights

AstraZeneca Licenses 3 X-Chem Drug Discovery Programs

(Page
1
of
1)

AstraZeneca (AZ) has agreed to license three drug discovery programs of X-Chem aimed at finding protein-protein interaction targets in oncology and respiratory/inflammation, as well as an antibacterial target, after achieving several milestones under a 16-month-old collaboration that was unannounced until now.

The value of the programs was not disclosed, though X-Chem—which announced the licensing deal—said the collaboration with AZ would enable to it receive an up-front payment and research funding, with the potential for payments tied to undisclosed discovery and clinical development milestones.

X-Chem said the licensing deal was based on the success of its small molecule drug discovery platform to discover novel, potent, and selective lead compounds against a range of targets.

“Today’s announcement illustrates X-Chem’s ability to serve as a leading source of novel small molecule therapeutics for our research partners. Our discovery platform capitalizes on multiple proprietary innovations in library design, screening methodology, and informatics that underlie its exceptional performance at identifying novel leads and addressing previously ‘undruggable’ targets,” X-Chem CEO Rick Wagner, Ph.D., said in a statement.

Mike Snowden, AZ’s vp of discovery sciences, said the collaboration with X-Chem “has enabled generation of novel chemical series for three of our key therapeutic programs and is an important part of our small molecule discovery strategy.”

AZ is one of several pharma giants, biotechnology organizations, and academic centers with which X-Chem says it has launched drug discovery collaborations in recent years.

Besides AZ, X-Chem has disclosed only one of those partners. In 2010, Roche agreed to apply X-Chem’s platform against several “high-value” therapeutic targets, in return for paying X-Chem up-front and research payments, additional payments tied to success-based discovery milestones, and technology access fees, plus potential developmental milestone payments and royalties based on worldwide sales of products developed with Roche. The pharma giant won rights to develop and commercialize any product arising from the collaboration.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

40.0%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

20.0%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.